The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

@article{Soler2001TheAA,
  title={The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.},
  author={M A Gonz{\'a}lez Soler and Jonathan Matz and Robert C. Townley and R. Buhl and J D O'brien and H. G. Fox and Jackie Thirlwell and Niroo Gupta and Giovanni Della Cioppa},
  journal={The European respiratory journal},
  year={2001},
  volume={18 2},
  pages={254-61}
}
The clinical benefit and steroid-sparing effect of treatment with the anti-immunoglobulin-E (IgE) antibody, omalizumab, was assessed in patients with moderate-to-severe allergic asthma. After a run-in period, 546 allergic asthmatics (aged 12-76 yrs), symptomatic despite inhaled corticosteroids (500-1,200 microg daily of beclomethasone dipropionate), were… CONTINUE READING